Vapotherm (NYSE:VAPO) Rating Lowered to Market Perform at William Blair

Vapotherm (NYSE:VAPOGet Rating) was downgraded by William Blair from an “outperform” rating to a “market perform” rating in a report released on Thursday, The Fly reports.

A number of other research analysts have also commented on VAPO. Canaccord Genuity Group lowered Vapotherm from a “buy” rating to a “hold” rating and cut their price target for the stock from $12.00 to $5.00 in a report on Friday, May 6th. Piper Sandler decreased their target price on Vapotherm from $2.50 to $2.00 and set an “underweight” rating on the stock in a report on Thursday. BTIG Research decreased their target price on Vapotherm from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, June 24th. Finally, Canaccord Genuity Group cut Vapotherm from a “buy” rating to a “hold” rating and decreased their price target for the company from $12.00 to $5.00 in a report on Friday, May 6th. One analyst has rated the stock with a sell rating and four have assigned a hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $4.75.

Vapotherm Stock Performance

Shares of VAPO opened at $1.80 on Thursday. Vapotherm has a 1 year low of $1.66 and a 1 year high of $31.87. The company has a market cap of $47.82 million, a price-to-earnings ratio of -0.49 and a beta of -0.22. The company has a debt-to-equity ratio of 1.79, a quick ratio of 3.75 and a current ratio of 5.37. The firm has a fifty day moving average of $2.56 and a 200-day moving average of $7.93.

Vapotherm (NYSE:VAPOGet Rating) last issued its quarterly earnings results on Wednesday, May 4th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.24). Vapotherm had a negative return on equity of 114.14% and a negative net margin of 102.94%. The business had revenue of $21.62 million during the quarter, compared to the consensus estimate of $21.03 million. During the same quarter last year, the firm posted ($0.40) earnings per share. Vapotherm’s revenue was down 33.1% compared to the same quarter last year. As a group, equities analysts anticipate that Vapotherm will post -3.07 earnings per share for the current year.

Insider Activity at Vapotherm

In other news, Director James W. Liken bought 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 11th. The shares were acquired at an average price of $2.98 per share, with a total value of $29,800.00. Following the transaction, the director now owns 134,378 shares in the company, valued at $400,446.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders have bought 40,000 shares of company stock valued at $122,700. 12.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Vapotherm

Hedge funds and other institutional investors have recently bought and sold shares of the company. Crow s Nest Holdings LP grew its stake in Vapotherm by 180.1% in the first quarter. Crow s Nest Holdings LP now owns 1,544,850 shares of the company’s stock valued at $21,473,000 after purchasing an additional 993,350 shares in the last quarter. Prescott General Partners LLC grew its stake in Vapotherm by 45.0% in the first quarter. Prescott General Partners LLC now owns 2,557,243 shares of the company’s stock valued at $35,546,000 after purchasing an additional 793,504 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in Vapotherm in the fourth quarter valued at approximately $10,339,000. Pier Capital LLC grew its stake in Vapotherm by 145.4% in the fourth quarter. Pier Capital LLC now owns 454,804 shares of the company’s stock valued at $9,419,000 after purchasing an additional 269,504 shares in the last quarter. Finally, Sio Capital Management LLC bought a new position in Vapotherm in the fourth quarter valued at approximately $3,728,000. Institutional investors and hedge funds own 69.67% of the company’s stock.

About Vapotherm

(Get Rating)

Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.

Featured Articles

The Fly logo

Analyst Recommendations for Vapotherm (NYSE:VAPO)

Want More Great Investing Ideas?

Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.